The CAM logo, showing the three letters C A M
Home page About the CAM website Contact CAM Search this site View current safety alerts Sign up to receive email updates Links to other useful sites Glossary of technical terms


Printer-friendly version of this page


Horse chestnut seed extract for the treatment of chronic venous insufficiency: additional references

The following references are additional to those already listed in the evidence summary for "Horse chestnut seed extract for the treatment of chronic venous insufficiency", listed on the following website: www.cam.org.nz.

  1. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy & Therapeutics. 2002;27(6):391-401.
  2. Abel M, Salm R, Goth D. Therapeutic regional anesthesia following an accidental intra-arterial injection. A case report on anesthesiologic care following incorrect injection of Reparil (sodium escinate) [German]. Anaesthesist. 1983;32(10):494-497.
  3. Albrecht D. Aescin for the treatment of edema in urology. [German]. Urologe. 1967;6(6):345-347.
  4. Alonso Ma J. Some frequently used plants are contraindicated in pregnant women. Circular Farmaceutica 1998;56(1):18-22.
  5. Amblard P. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency - Comment. Annales De Dermatologie Et De Venereologie 1997;124(10):755-755.
  6. Anonymous. Micronised purified flavonoid fraction: a phlebotropic agent that is useful in the treatment of chronic venous insufficiency and venous ulcer. Drugs & Therapy Perspectives 2003;19(11):1-4.
  7. Argento A, Tiraferri E, Marzaloni M. Interaction between oral anticoagulats and herbal medicines. An emerging problem. Annali Italiani di Medicina Interna 2000;15(2):139-143.
  8. Argento A, Tiraferri E, Marzaloni M. Oral anticoagulants and medicinal plants. An emerging interaction. [Italian]. Annali Italiani di Medicina Interna. 2000;15(2):139-143.
  9. Arnould T, Janssens D, Michiels C, Remacle J. Effect of aescine on hypoxia-induced activation of human endothelial cells. European Journal of Pharmacology. 1996;315(2):227-233.
  10. Bamonte F, Craveri F, Crema A, De Pascale V. Toxicological observations after the intravenous administration of an aescin-cyclonamine combination. Bollettino Chimico Farmaceutico 1976;115(Mar):272-284.
  11. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: efficacy and safety. British Journal of Clinical Pharmacology 2003;55(4):331-340.
  12. Bassler D, Okpanyi S, Schrodter A, Loew D, Schurer M, Schulz HU. Bioavailability of beta-aescin from horse chestnut seed extract: comparative clinical studies of two galenic formulations. Advances in Therapy 2003;20(5):295-304.
  13. Bastian HP, Vahlensieck W. Renal function under parenteral application of aescinat. [German]. Medizinische Klinik. 1976;71(32-33):1295-1299.
  14. Beck M. Horse chestnut seed extract. Lancet. 1990;335(8703):1467.
  15. Belcaro G, Nicolaides AN, Geroulakos G, Cesarone MR, Incandela L, De Sanctis MT. Essaven gel: review of experimental and clinical data. Angiology 2001;52(SUPPL. 3):S1-S4.
  16. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002;9:1.
  17. Bielanski TE, Piotrowski ZH. Horse-chestnut seed extract for chronic venous insufficiency. Journal of Family Practice. 1999;48(3):171-172.
  18. Blumenthal M. The complete German Commission E monographs: therapeutic guide to herbal medicines. Boston, MA.: American Botanical Council; 1998.
  19. Bougelet C, Roland IH, Ninane N, Arnould T, Remacle J, Michiels C. Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. European Journal of Pharmacology. 1998;345(1):89-95.
  20. Brandis M, Krohn HP, Offner G, Onken D, Brodehl J. Acute renal failure after intracranial injury in three children: analysis of possible causes. [German]. Deutsche Medizinische Wochenschrift. 1975;100(22):1244-1247.
  21. Bronzi G, Marini L, Frassanito S. Phytotherapy in peripheral venous insufficiency and peripheral associated panniculitis. [Italian]. Quaderni di Medicina e Chirurgia 2001;17(2-3):280-283.
  22. Brunner F, Hoffmann C, Schuller-Petrovic S. Responsiveness of human varicose saphenous veins to vasoactive agents. British Journal of Clinical Pharmacology 2001;51(3):219-224.
  23. Bucci A, Scarno AG, Lalloni L, Pacillo L, Azzarri L, Azzarri A, et al. Peripheral venous stasis in females: treatment with a combination of phosphatidylcholine and escin. [Italian]. Clinica e Terapia Cardiovascolare 1990;9(1):25-33.
  24. Cacciatore E. Venotrophic therapy in the integrated treatment of patients with venous diseases. [Italian]. Minerva Cardioangiologica. 1977;25(6):499-508.
  25. Cebo B, Krupinska J, Sobanski H, Mazur J, Czarnecki R. Pharmacological properties of saponin fractions from domestic crude drugs: Saponaria officinalis, Primula officinalis and Aesculus hippocastanum. Herba Polonica 1976;22(2):154-162.
  26. Cervenakov I, Fillo J, Mardiak J, Kopecny M, Smirala J, Lepies P. Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker - Tamsulosin. International Urology & Nephrology 2002;34(1):25-29.
  27. Cesarone MR, De Sanctis MT, Incandela L, Belcaro G, Griffin M. Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel - A placebo-controlled, randomized study. Angiology 2001;52:S11-S16.
  28. Cesarone MR, Incandela L, Belcaro G, De Sanctis MT, Ricci A, Griffin M. Two-week topical treatment with Essaven gel in patients with diabetic microangiopathy: a placebo-controlled, randomized study. Angiology 2001;52(SUPPL. 3):S43-S48.
  29. Chaika LA, Khadzhai Ia I. Membrane stabilizing effect of medicinal substances used for the treatment of chronic venous insufficiency. [Russian]. Farmakologiia i Toksikologiia. 1977;40(3):306-309.
  30. Clement DL. Venous ulcer reappraisal: insights from an international task force. Journal of Vascular Research 1999;36(SUPPL. 1):42-47.
  31. Collier TK, Stein JE, Wallace RJ, Varanasi U. Xenobiotic metabolizing enzymes in spawning English sole (Parophrys vetulus) exposed to organic-solvent extracts of marine sediments from contaminated and reference areas. Comparative Biochemistry & Physiology. C, Comparative Pharmacology & Toxicology. 1986;84(2):291-298.
  32. Cook D, Laporta D, Skrobik Y, Peters S, Sharpe M, Murphy P, et al. Prevention of venous thromboembolism in critically III surgery patients: a cross-sectional study. Journal of Critical Care 2001;16(4):161-166.
  33. Dattner AM. From medical herbalism to phytotherapy in dermatology: back to the future. Dermatologic Therapy 2003;16(2):106-113.
  34. De Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Griffin M. Treatment of superficial vein thrombosis with standardized application of Essaven gel: a placebo-controlled, randomized study. Angiology 2001;52(SUPPL. 3):S57-S62.
  35. De Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Ricci A, Griffin M. Four-week treatment with Essaven gel in diabetic microangiopathy: a placebo-controlled, randomized study. Angiology 2001;52(SUPPL. 3):S49-S55.
  36. De Sanctis MT, Incandela L, Belcaro G, Cesarone MR. Topical treatment of venous microangiopathy in patients with venous ulceration with Essaven gel: a placebo-controlled, randomized study. Angiology. 2001;52(Suppl 3):S29-34.
  37. Desogus AI, D'Alia G. Venotropic therapy: results of clinical experimentation. [Italian]. Clinica Terapeutica. 1986;118(5):339-342.
  38. Diehm C, Trampisch HJ, Lange S, Schmidt C. Horse-chestnut seed extract for chronic venous insufficiency - reply. Lancet 1996;347(9009):1183-1183.
  39. Dini D, Bianchini M, Massa T, Fassio T. Treatment of upper limb lymphedema after mastectomy with escine and levo-thyroxine. [Italian]. Minerva Medica. 1981;72(35):2319-2322.
  40. Ebell M. Is horse-chestnut seed extract effective for the treatment of chronic venous insufficiency? Evidence-Based Practice 1999;2(3):4.
  41. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. Medical Journal of Australia 1999;171(11-12):604-608.
  42. Eichlisberger R, Holtz D, Stirnemann P, Jager KA. Ambulatory treatment of varicose veins. [German]. Therapeutische Umschau 1996;53(4):295-303.
  43. el-Dessouki S. Aflatoxins in cosmetics containing substrates for aflatoxin-producing fungi. Food & Chemical Toxicology. 1992;30(11):993-994.
  44. Ernst E, Pittler MH, Stevinson C. Complementary/alternative medicine in dermatology: evidence-assessed efficacy of two diseases and two treatments. American Journal of Clinical Dermatology. 2002;3(5):341-348.
  45. Ernst E. Herbal medications for common ailments in the elderly. Drugs & Aging. 1999;15(6):423-428.
  46. Ernst E. Research priorities in CAM. Complementary Therapies in Medicine 2001;9(3):186-187.
  47. Escribano MM, Munoz-Bellido FJ, Velazquez E, Delgado J, Serrano P, Guardia J, et al. Contact urticaria due to aescin. Contact Dermatitis. 1997;37(5):233.
  48. Fabrizio Saettone M, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four beta-blockers, and in vitro/in vivo toxic activity. International Journal of Pharmaceutics 1996;142(1):103-113.
  49. Falco G, Gomez-Catalan J, Llobet JM, Domingo JL. Contribution of medicinal plants to the daily intake of various toxic elements in Catalonia, Spain. Trace Elements & Electrolytes 2003;20(2):120-124.
  50. Felix W. Pharmacokinetic of oedema protective drugs. Phlebologie 1999;28(4):105-111.
  51. Felix W. The problem of "anti-venous insufficiency agents". [German]. Medizinische Welt. 1980;31(21):813-816.
  52. Filip K. Sufficient dosage of edema protective agents. [German]. Praxis Med 1997;6(7).
  53. Foldi M. On randomized clinical trials. Lymphology. 1997;30(2):46-48.
  54. Franzini M, Bignamini A, Micheletti P, Valdenassi L, Agostini G, Richelmi P, et al. Subcutaneous oxygen-ozone therapy in indurative hypodermatitis and in localised lipodystrophies: A clinical study of efficacy and tolerability. Acta Toxicologica et Therapeutica 1993;14(4):273-288.
  55. Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and daflon. Angiology. 2000;51(3):197-205.
  56. Gallelli L, Guadagnino V, Caroleo B, Marigliano N, De Sarro GB, Izzi A. Bilateral skin ulceration after injection of pegylated interferon-a -2b in a patient with chronic hepatitis C. Clinical Drug Investigation 2003;23(9):615-619.
  57. Gasbarro V, Vettorello GF. Treating cellulite. Cosmetics & Toiletries 1992;107(Dec):64-66.
  58. Gatta L, Corti G, Bernasconi S, Gatta E. Treatment of remote sequelae of deep venous thrombosis of the lower extremities. [Italian]. Clinica Terapeutica. 1978;87(5):499-501.
  59. Gerova Z, Stvrtinova V, Sefranek V, Illek B. Beta-aescin in the treatment of chronic venous insufficiency. [Slovak]. Casopis Lekaru Ceskych 1991;130(1):15-19.
  60. Gorey JD, Wahlqvist ML, Boyce NW. Adverse reaction to a Chinese herbal remedy. Medical Journal of Australia 1992;157(7):484-486.
  61. Grases F, Costa-Bauza A, Garcia-Gonzalez R, Payeras A, Bassa A, Torres JJ, et al. Indinavir crystallization and urolithiasis. International Urology & Nephrology. 1999;31(1):23-29.
  62. Greeske K. Rational vein therapy with herbaceous agents. [German]. Pharmazeutische Zeitung 1994;139(21):9-13.
  63. Grob PJ, Muller-Schoop JW, Hacki MA, Joller-Jemelka HI. Drug-induced pseudolupus. Lancet 1975;2(Jul 26):144-148.
  64. Gruenwald J. PDR for herbal medicines. Montvale, NJ.: Medical Economics Company; 1998.
  65. Guilhou JJ. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency - Commentary. Annales De Dermatologie Et De Venereologie 1997;124(10):755-755.
  66. Haupt H. Toxic and less toxic plants: 48. [German]. Kinderkrankenschwester. 2000;19(8):337.
  67. He J. Aescine in treatment of facial neuritis. Zhongguo Xinyao Yu Linchuang Zazhi 2002;21(4):224-225.
  68. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. American Journal of Health-System Pharmacy. 2000;57(13):1221-1227; quiz 1228-1230.
  69. Henry F, Paquet P, Pierard-franchimont C, Pierard GE. Leg heaviness and stasis microangiopathy. Preventive and therapeutic measures. [French]. Revue Medicale de Liege 2003;58(6):435-438.
  70. Hirsch J. Leg disorders: disorders of blood supply. The effect of Essaven ultra in chronic venous insufficiency. [German]. Fortschritte der Medizin. 1982;100(10):436-438.
  71. Hitzenberger G. The therapeutic effectiveness of chestnut extract. [German]. Wiener Medizinische Wochenschrift. 1989;139(17):385-389.
  72. Hoffmann J, Day UH, Schneider B, Bohnert KJ. Percutaneous therapy of chronic-venous insufficiency by aescin gel. [German]. Medizinische Welt 1988;39(30-31):951-955.
  73. Hostettmann K, Hamburger M. Components and pharmacology of phytopharmaceutic preparations for varicose veins. [German]. Phlebologie 1994;23(3):71-77.
  74. Hubner G, Wray V, Nahrstedt A. Flavonol oligosaccharides from the seeds of aesculus hippocastanum. Planta Medica 1999;65(7):636-642.
  75. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M. Changes in microcirculation in venous ulcers with essaven gel: a pilot, cross-over, placebo-controlled, randomized study. Angiology 2001;52(SUPPL. 3):S23-S27.
  76. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M. Microangiopathy and venous ulceration: topical treatment with essaven gel: a placebo-controlled, randomized study. Angiology 2001;52:S17-S21.
  77. Incandela L, Belcaro G, Nicolaides AN, Geroulakos G, Cesarone MR, De Sanctis MT. Microcirculation after standardized application of Essaven gel on normal skin: a placebo-controlled, randomized study. Angiology 2001;52(SUPPL. 3):S5-S10.
  78. Incandela L, De Sanctis MT, Cesarone MR, Ricci A, Errichi BM, Dugal M, et al. Treatment of superficial vein thrombosis: clinical evaluation of essaven gel: a placebo-controlled, 8-week, randomized study. Angiology 2001;52(SUPPL. 3):S69-S72.
  79. Jansen W, Wienert V. The effect of aescin on capillary filtration. [German]. Phlebologie und Proktologie 1989;18(4):201-203.
  80. Jaspersen-Schib R, Theus L, Guirguis-Oeschger M, Gossweiler B, Meier-Abt PJ. Acute poisonings with toxic plants in Switzerland between 1966 and 1994. Schweizerische Medizinische Wochenschrift 1996;126(25):1085-1098.
  81. Jaspersen-Schib R, Theus L, Guirguis-Oeschger M, Gossweiler B, Meier-Abt PJ. Serious plant poisonings in Switzerland 1966-1994. Case analysis from the Swiss Toxicology Information Center [German]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine. 1996;126(25):1085-1098.
  82. Jautova J, Jarcuskova D, Benecova K, Cider V, Frankovicova M. Nicolau's syndrome as a complication after administration of depot pollen vaccine. Ceskoslovenska Dermatologie 1996;71(2):75-78.
  83. Kamenicek V, Holan P, Franek P. Systemic enzyme therapy in the treatment and prophylaxis of posttraumatic swelling. Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca 2001;68(1):45-49.
  84. Kiesewetter H, Jung F, Junger M, Marx U, Koscielny J. Chronic venous insufficiency: only a macro- or also a microangiopathy? Clinical Hemorheology 1994;14(SUPPL. 1):S65-S78.
  85. Kurz H. Varices and vein drugs. [German]. Pharmazeutische Zeitung 1989;134(5):32-34.
  86. Lange S, Freitag G, Trampisch HJ. Practical experience with the design and analysis of a three-armed equivalence study. European Journal of Clinical Pharmacology. 1998;54(7):535-540.
  87. Leach M. Aesculus hippocastanum. Australian Journal of Medical Herbalism 2001;13(4):136-140.
  88. Lisi DM. Availability and uses of FDA unsafe herbs on the Internet. ASHP Midyear Clinical Meeting 1998;33(Dec).
  89. Loew D, Kaszkin M. Approaching the problem of bioequivalence of herbal medicinal products. Phytotherapy Research 2002;16(8):705-711.
  90. Loew D, Schwankl W. Symptomatic treatment of chronic venous insufficiency (CVI) with herbal medicinal products. Perfusion 2001;14(1):9.
  91. Lorenz D, Marek ML. Das therapeutische wirksame prinzip der rosskastanie (aesculus hippocastanum). [German]. Arzneimittelforschung 1960;10:263-272.
  92. Ludwig M, Glanzer K. Determination of the cross-sectional area and blood flow velocity in the femoral vein using duplex sonography: a possibility for assessing the effect of drugs acting on veins. [German]. Vasa - Supplementum. 1987;20:290-293.
  93. Markwardt F. Pharmacology of oedema protective drugs. Phlebology 1996;11(1):10-15.
  94. Marshall M, Wustenberg P. Pharmacotherapy in the treatment of chronic venous-lymphatic insufficiency. [German]. Therapiewoche 1994;44(23):1333-1338.
  95. Marshall M. Drug therapy of chronic venous disorders: tissue protection and relief of symptoms. [German]. Therapiewoche 1993;43(34-35):1726-7131.
  96. Mascolo N, Borrelli F, Capasso R, Capasso F, Di Carlo G, Izzo AA, et al. Natural products and cardiovascular disturbances. Phytotherapy Research 1998;12(SUPPL. 1):S121-S123.
  97. Matsuda H, Li Y, Murakami T. Effects of escins Ia, Ib, IIa, IIb from the horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biological and Pharmaceutical Bulletin 1997;20:1092-1095.
  98. Matsuda H, Li Y, Yoshikawa M. Gastroprotections of escins Ia, Ib, IIa, and IIb on ethanol-induced gastric mucosal lesions in rats. European Journal of Pharmacology. 1999;373(1):63-70.
  99. Melchart D. Horse-chestnut seed extract for chronic venous insufficiency: a systematic review. Focus on Alternative & Complementary Therapies 1999;4(3):128-129.
  100. Michiels C, Bouaziz N, Remacle J. Role of the endothelium and blood stasis in the appearance of varicose veins. International Angiology 2002;21(2 SUPPL. 1):18-25.
  101. Michiels C, Remacle J, Bouaziz N. Endothelium and venotropic drugs in chronic venous insufficiency: a review. Phlebology 2002;17(3-4):145-150.
  102. Mills S, Bone K. Principles and practice of phytotherapy: modern herbal medicine. London: Churchill Livingstone; 1999.
  103. Minar E. Conservative treatment of varicosis and chronic venous insufficiency. [German]. Acta Chirurgica Austriaca 1998;30(2):89-92.
  104. Mingrino S, Scanarini M. Anti-edema effect of escin at the cerebral level. [Italian]. Minerva Anestesiologica. 1978;44(6):355-360.
  105. Montagnani A. Treatment of chronic venous insufficiency with phlebotropic drugs. [Italian]. Clinica Terapeutica. 1984;108(2):91-98.
  106. Myers SP. Interactions between complementary medicines and warfarin. Australian Prescriber 2002;25(3):54-56.
  107. Nappi R. A new non-corticoid preparation with an escin base in topical treatment of the ano-rectal varicose syndrome [Italian]. Clinica Terapeutica. 1978;86(3):219-228.
  108. Navratilova Z, Semradova V. Local application of heparin: possibility of its use in phlebology. [Czech]. Ceskoslovenska Dermatologie 2000;75(5):230-232.
  109. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press; 1996.
  110. Ottillinger B, Greeske K. Rational therapy of chronic venous insufficiency: chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovascular Disorders. 2001;1(1):5.
  111. Pabst H, Segesser B, Bulitta M, Wetzel D, Bertram S. Efficacy and tolerability of escin/diethylamine salicylate combination gels in patients with blunt injuries of the extremities. International Journal of Sports Medicine. 2001;22(6):430-436.
  112. Panigati D. The pharmacology of escin, a saponin of Aesculus hippocastanum L. III. Pharmacokinetics and toxicology [Italian]. Bollettino Chimico Farmaceutico. 1992;131(8):320-321.
  113. Piller NB. A comparison of the effectiveness of some anti-inflammatory drugs on thermal oedema. British Journal of Experimental Pathology. 1975;56(6):554-559.
  114. Pirard J, Gillet P, Guffens JM, Defrance P. Double blind study of reparil in proctology. [French]. Revue Medicale de Liege. 1976;31(10):343-345.
  115. Pohlmann BK. Chronic vein insufficiency: only adequate treatment can prevent chronicity. [German]. Zeitschrift fur Allgemeinmedizin 1995;71(24).
  116. Pohlmann G, Bar H, Figulla HR. Studies on dose dependency of the edema protective effect of extracts from horse chestnut in female patients suffering from chronic venous insufficiency. [German]. Vasomed 2000;12(2):69-75.
  117. Przybojewska B, Baranski B, Spiechowicz E, Dziubaltowska E, Szymczak W. Potential carcinogenicity assessment of alpha-aescin and phenbendasol. Acta Poloniae Pharmaceutica. 1994;51(1):89-93.
  118. Pytlik M, Janiec W, Cegiela U, Sliwinski L. Influence of alpha-escin on the femoral bone strength in ovariectomized rats. Polish Journal of Pharmacology. 1999;51(6):511-515.
  119. Raake W, Binder M. Treatment of superficial thrombophlebitis. [German]. Hamostaseologie 2002;22(4):149-153.
  120. Ramelet AA. Therapeutic strategy in venous disease: value of phlebotropic drugs. Phlebolymphology. Issue 1998;19(pp 3-7).
  121. Regenthal R, Voigt H, Grossmann K. Possibilities and limits of the pharmacotherapy of the chronic venous insufficiency. [German]. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1990;45(4):108-113.
  122. Reuter HD. Phytopharmaca research 2000. Report on the Joint Symposium of the Society for Phytotherapy and the Society for Medicinal Plant Research, November 27-28, 1998 in Bonn. Zeitschrift fur Phytotherapie 1999;20(1):10-21.
  123. Rivano C, Rosadini G. Escin in the treatment of cerebral edema. Clinical and electroencephalographic study with correlographic analysis and spectrum of action. [Italian]. Minerva Neurochirurgica. 1969;13(1):92-94.
  124. Rotblatt MD, Ziment I. Evidence-based herbal medicine. Philadelphia: Hanley & Belfus; 2002.
  125. Rotblatt MD. Cranberry, feverfew, horse chestnut, and kava. Western Journal of Medicine 1999;171(3):195-198.
  126. Russell AS. Drug-induced autoimmune disease. Clinics in Immunology and Allergy 1981;1:57-76.
  127. Saenko VF, Sukharev, II, Viktorov AP, Goloopykho LI. Experience with the clinical use of essaven gel in treating venous diseases. [Russian]. Klinicheskaia Khirurgiia. 1996(7):13-14.
  128. Salviano PA, Fiocchi CC. Phlebotropic phytomedicines for the symptomatic medication/treatment of varices and hemorrhoids - Bibliographical update. [Portuguese]. Revista Brasileira de Medicina 2001;58(4):257-262.
  129. Sameshima H, Ohmori M, Haraguchi T, Nishimura Y, Teraoka A, Nishizaki M. A single dose oral toxicity study of AK-4 granule in beagle dogs and rats. Japanese Pharmacology & Therapeutics 1994;22(11):115-118.
  130. Schlenzka K. Treatment by natural remedies in phlebology. [German]. Phlebologie 2003;32(3):60-64.
  131. Schonwald D. Phytotherapy in chronic venous insufficiency. [German]. Pharmazeutische Zeitung 1990;135(15).
  132. Schrader E, Schwankl W, Sieder C, Christoffel V. Comparative study of the bioavailability of beta-escine after single oral administration of two different drug formulations containing an extract of horse-chestnut seeds [German]. Pharmazie 1995;50(9):623-627.
  133. Schulz M, Morck H. Self-medication for hemorrhoids? Pharmazeutische Zeitung 1992;137(46):9-18.
  134. Schwarz B. Chronic vein insufficiency. [German]. Pharmazeutische Zeitung 1995;140(17):59-60.
  135. Severin E, Mladovan G. Evaluation of the efficacy of a phlebotropic drug by the doppler method. [Italian]. Minerva Cardioangiologica. 1988;36(7-8):375-376.
  136. Simini B. Horse-chestnut seed extract for chronic venous insufficiency. Lancet. 1996;347(9009):1182-1183.
  137. Simon J, Brodsky A, Famaey JP. Randomized, double-blind study of the efficacy and tolerability of proglumetacin versus diclofenac in sports trauma. Current Therapeutic Research, Clinical & Experimental 1993;53(6):630-634.
  138. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacological Research. 2001;44(3):183-193.
  139. Smith PDC. The microcirculation in venous hypertension. Vascular Medicine 1997;2(3):203-213.
  140. Steiner M. Conservative therapy of chronic venous insufficiency. The extent of the edema-preventive effect of horse chestnut seed extract [German]. Vasa - Supplementum. 1991;33:217.
  141. Steiner M. Investigation on the edema-reducing and edema-protective effect of horse chestnut seed extract. [German]. Phlebologie und Proktologie 1990;19(5):239-242.
  142. Stoika RS, Antonyuk VO, Yakymovych IA, Yakymovych MYA, Korchynsky OG, Preobrazhenska OV, et al. Tumor cell response to cytotoxic lectins and heat shock in vitro: study of possible involvement of transforming growth factor beta1. International Journal of Medicine, Biology & the Environment 2000;28(1):65-69.
  143. Szydlowska H, Zaporowska E, Kuszlik-Jochym K, Korohoda W, Branny J. Membranolytic activity of detergents as studied with cell viability tests. Folia Histochemica et Cytochemica. 1978;16(2):69-78.
  144. Thesen R, Schulz M, Braun R. Totally or partly 'negative' drugs. Pharmazeutische Zeitung 1994;139(13):37-39.
  145. Tiffany NUCBSSMDCBHBEBEPSDSP, Leach M. Horse chestnut: a multidisciplinary clinical review
  146. Tolino A. Medical treatment of the anorectal varicose syndrome in gynecology and obstetrics. [Italian]. Minerva Ginecologica. 1979;31(3):169-174.
  147. Tumino G, Berni A, Tromba L, Marignetti L. Evaluation of the therapeutic effect of a phlebotropic drug with a new noninvasive method: rheography by reflected light [Italian]. Clinica Terapeutica. 1987;122(3):189-194.
  148. Turio E, Romanelli M, Barachini P. Clinical arid instrumental evaluation of the efficacy of a vasoactive drug containing vitamin PP, vitamin C and phyto-therapeutic extracts titrated in escin, bromelain and anthocyanosides for the treatment of varicose leg ulcers. [Italian]. Giornale Italiano di Dermatologia e Venereologia 2000;135(1):101-105.
  149. Tzavellas O, Finke J. Aescin (Reparil) in cerebral circulation disorders. Clinical and ophthalmodynamographic observations [German]. Wiener Klinische Wochenschrift. 1970;82(41):714-716.
  150. Ulbricht C, Tiffany N, Bent S, Smith M, Boon H, Basch E, et al. Horse chestnut: a multidisciplinary clinical review. Journal of Herbal Pharmacotherapy 2002;2(1):71-85.
  151. Ulicna O, Cizova M, Valachova A, Brixova E. The effect of beta-escin on metabolism in experimental liver steatosis in rats. [Slovak]. Bratislavske Lekarske Listy. 1994;95(11):505-511.
  152. Vargova M, Kobzova D, Gajdova M, Jakubovsky J, Lipkova V, Stenclova R, et al. Oral toxicity of beta-aescin (active ingredient of Yellon Gel). I. One-month toxicity study in rats. II. Three-month toxicity study in rats. Farmako/Terapeuticke Zpravy 1988;34(3):193-221.
  153. Vayssairat M, Debure C, Maurel A, Gaitz JP, Simini B, Diehm C, et al. Horse-chestnut seed extract for chronic venous insufficiency. Lancet 1996;347(9009):182-183.
  154. Virgini-Magalhaes CE, Bottino DA, Bouskela E. Microcirculation and CVI: from production of pharmacological models to discovery of new therapies. Phlebolymphology. Issue 2001;35(pp 16-19).
  155. Vogel G, Marek ML, Oertner R. Studies on the mechanism of the therapeutic and toxic action of the horse chestnut saponin aescin [German]. Arzneimittel-Forschung. 1970;20(5):699-703.
  156. Voigt E, Junger H. Acute posttraumatic renal failure following therapy with antibiotics and beta-aescin. [German]. Anaesthesist. 1978;27(2):81-83.
  157. von Kreybig T, Prechtel K. Studies on toxicity and fertility of escin in the rat. [German]. Arzneimittel-Forschung. 1977;27(7):1465-1466.
  158. Walli F, Grob PJ, Muller-Schoop J. Pseudo-venocuran-lupus: a minor episode in the history of medicine. [German]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine. 1981;111(38):1398-1405.
  159. Weihmayer T. Ponderousness, pain and cramp. Part 8: alternative medicine in the therapy of varicosis and vein insufficiency. [German]. Fortschritte der Medizin 1995;113(30).
  160. Wijnsma R, Woerdenbag HJ, Busse W. The importance of Arnica-species in phytomedicine. Zeitschrift fur Phytotherapie 1995;16(1):48-62.
  161. Wilkinson JA, Brown AMG. Horse chestnut: aesculus hippocastanum: potential applications in cosmetic skin-care products. International Journal of Cosmetic Science 1999;21(6):437-447.
  162. Williams MC, Olsen JD. Toxicity of seeds of three Aesculus sp. to chicks and hamsters. American Journal of Veterinary Research. 1984;45(3):539-542.
  163. Wolthuis A, Nackaerts K, Guffens P, Jousten P, Demedts M. Minocycline-associated pulmonary infiltrates and eosinophilia. Acta Clinica Belgica 2003;58(1):50-53.
  164. Wuppermann T. Therapy of chronic venous disease. [German]. Fortschritt und Fortbildung in der Medizin 1996;20.
  165. Yuwono HS. Diagnosis and treatment in the management of chronic venous insufficiency. Clinical Hemorheology & Microcirculation 2000;23(2-4):233-237.
  166. Zhao JL, Li C, Bai XY. Aescine in treatment of lumbar intervertebral disc prolapse. China Pharmacist 2001;20(3):163-164.


Back to evidence summary

DISCLAIMER: This website does not provide specific medical advice and the information provided should not be used as a substitute for seeking medical advice from a registered health practitioner. Full disclaimer . . .


Links  |   Glossary  |   Site map  |   Disclaimer  |   Copyright